Therefore, in the present study, we prospectively assessed AS changes on a daily basis before and immediately after the initiation of a new, highly effective CFTR-modulating ETI therapy in 45 pwCF using a novel PROM, the novel CF-specific GI-symptom diary “CFAbd-day2day©”. Here, CFTR is linked to cystic fibrosis.